Compare Lockheed Martin Corporation (LMT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Repligen Corporation Common Stock — how do they compare? Lockheed Martin Corporation trades at $522.91 (market cap $116.32B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Lockheed Martin Corporation is far larger — about 10.4× Repligen Corporation Common Stock's market cap, and Lockheed Martin Corporation pays a 2.86% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and Repligen Corporation Common Stock for 0 Days on average.
| LMT | RGEN | |
|---|---|---|
Market Cap | $116.32B | $11.14B |
Volume | 860,316 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $676.70 | $194.57 |
52-Week Low | $439.19 | $102.87 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $133.07B | $11.02B |
Dividend Yield | 2.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $522.23, up 2.02% today, with a bearish technical signal and neutral oscillators. The company reported revenue of $75.05 billion in 2025, with net income of $5.02 billion, though recent quarters show mixed earnings results. Analysts maintain a strong buy consensus with a $625.64 price target. Recent news highlights ongoing dividend increases, AI integration efforts, and new defense contracts, supporting long-term growth prospects amid stable cash flows.
The outlook for LMT is positive, driven by robust defense spending and strategic innovations, but risks include reliance on government contracts and fixed-price contract volatility. The stock offers value with a P/E of 18.58 and a dividend yield supported by 23 years of increases, though technical indicators suggest near-term caution.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
